Further Evidence in Favor of Non-Invasive Vasospasm Diagnosis

Non-invasive coronary vasospasm diagnosis by means of echocardiography with the administration of ergonovine can be performed safely; even without prior angiography to rule out fixed lesions.

These data are encouraging and move patients with vessel spasm but without significant lesions away from multiple angiographies and from the uncertainty of a diagnosis “by exclusion.”

This work recently published in JACC Cardiovasc Imaging sought large-scale evidence to support the clinical utility of ergonovine echocardiography for the diagnosis of coronary spasms.

The test was performed in 14,012 patients (mean age 52 years; 44.3% were women) after ruling out significant coronary arterial stenosis by functional (stress electrocardiography or single photon emission computed tomography [SPECT], n = 9,824) or anatomic testing (tomography or conventional angiography, n = 4,188).

Only 0.4% of patients had to stop the study early, and a positive result was obtained in 2144 patients (15.3%). Said positive result had variable frequencies according to the presumptive diagnosis for each patient at baseline (acute coronary syndrome [38.2%], variant angina [31.8%], effort angina [14.9%], aborted sudden cardiac death [17.6%], and syncope [9.9%]).


Read also: Diabetes Could Decide between Ticagrelor and Prasugrel.


There were no mortality or infarction events during the study with ergonovine.

During a median follow-up of 11.4 years (range: 7.2 to 15.8), all-cause death and cardiovascular death occurred in 494 and 143 patients, respectively.

Compared with patients with positive ergonovine test results, the functional test group and the anatomic test group did not show a significant difference in events.


Read also: How To De-Escalate Prasugrel After Acute Coronary Syndrome?


After multiple adjustments, having a positive ergonovine echocardiogram was an independent factor linked to all-cause mortality (hazard ratio [HR]: 1.879, p < 0.001) and cardiovascular death (HR: 2.903, p < 0.001).

Conclusion

Ergonovine echocardiography may be a safe diagnostic tool for coronary vasospasm, even without anatomic documentation. These results have major long-term prognosis implications, and might even replace invasive provocation testing.

Original Title: Diagnostic and Prognostic Value of Ergonovine Echocardiography for Noninvasive Diagnosis of Coronary Vasospasm.

Reference: Sang Yong Om et al. JACC Cardiovasc Imaging. 2020 Sep;13(9):1875-1887. doi: 10.1016/j.jcmg.2020.03.008.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...

Is IVUS Always Necessary for Left Main Coronary Artery PCI?

Percutaneous coronary intervention (PCI) of the unprotected left main coronary artery is a highly complex procedure because of the large amount of myocardium at...

Dual-Prep Registry: Atherectomy and IVL for Severe Coronary Calcification

Severe coronary calcification remains one of the most challenging scenarios in percutaneous coronary intervention (PCI). Although rotational or orbital atherectomy and intravascular lithotripsy (IVL)...

Prehospital heparin in STEMI: A safe strategy associated with improved early reperfusion

Early reperfusion remains the main prognostic determinant in patients with ST-segment elevation myocardial infarction (STEMI). Although primary percutaneous coronary intervention (PCI) is the treatment...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...